Evidence map›Paper›PMID 34760008›Full record

ArticleResearch in pharmaceutical sciences2021

QSAR analysis of pyrimidine derivatives as VEGFR-2 receptor inhibitors to inhibit cancer using multiple linear regression and artificial neural network.

Fariba Masoomi Sefiddashti, Saeid Asadpour, Hedayat Haddadi, Shima Ghanavati Nasab

Open access · goldAbstract read
In one paragraph

Article in Research in pharmaceutical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fariba Masoomi SefiddashtiDepartment of Chemistry, Faculty of Sciences, Shahrekord University, Shahrekord, I.R. Iran.
Saeid AsadpourDepartment of Chemistry, Faculty of Sciences, Shahrekord University, Shahrekord, I.R. Iran.
Hedayat HaddadiDepartment of Chemistry, Faculty of Sciences, Shahrekord University, Shahrekord, I.R. Iran.
Shima Ghanavati NasabDepartment of Chemistry, Faculty of Sciences, Shahrekord University, Shahrekord, I.R. Iran.
Shahrekord University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeIn this study, the pharmacological activity of 33 compounds of furopyrimidine and thienopyrimidine as vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors to inhibit cancer was investigated. The most important angiogenesis inducer is VEGF endothelial growth factor, which exerts its activity by binding to two tyrosine kinase receptors called VEGFR-1 and VEGFR-2. Due to the critical role of VEGF in the pathological angiogenesis of this molecule, it is a valuable therapeutic target for anti-angiogenesis therapies. EXPERIMENTAL APPROACH: After calculating descriptors using SPSS software and stepwise selection method, 5 descriptors were used for modeling in multiple linear regression (MLR) and artificial neural network (ANN). The calibration series and the test series in this study included 26 and 7 combinations, respectively. FINDINGS/

resultsThe performance evaluation of models was determined by the R CONCLUSION AND IMPLICATIONS: The results were evaluated by different statistical methods and it was concluded that the nonlinear neural network method is powerful to predict the pharmacological activity of similar compounds, and because of the complex and nonlinear relationships, the MLR was not capable of establishing a good model with high predictive power.

Indexed as

Artificial neural networkCancerMultiple linear regressionPyrimidine derivativesQSAR

Identifiers

PMID34760008
PMCPMC8562410
OpenAlexW3206445358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.